I. AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application:

Claims 1-7 (cancelled)

Claim 8 (currently amended): A method for the treatment of retina or optic nerve head neuropathy associated with glaucoma which comprises administering to a mammal a composition comprising an effective amount of one or more non-peptide neurotrophic factor stimulator(s) and a pharmaceutically acceptable vehicle, wherein said composition is administered topically or intraocularly.

Claim 9 (previously presented): A method according to Claim 8, wherein the neurotophic factor stimulator is selected from the group consisting of: AIT-082 (neotrofin), ONO-2506, CB-1093, NS521 ((1-(1-butyl)-4-(2-oxo-1-benzimidazolone) piperidine, SS-701, KT-711 and clenbuterol.

Claim 10 (original): A method according to claim 9, wherein the neurotrophic factor stimulator is AIT-082 (neotrofin).

Claim 11-14 (cancelled)

Claim 15 (new): The method of claim 8, wherein the composition is administered by intraocular injection prior to ocular surgery.

Claim 16 (new): The method of claim 8, wherein the composition is administered by intraocular injection during ocular surgery.

Claim 17 (new): The method of claim 8, wherein the composition is administered by intraocular injection prior to and during ocular surgery.

Claim 18 (new): The method of claim 15, wherein the composition is a balanced salt irrigating solution.

Claim 19 (new): The method of claim 16, wherein the composition is a balanced salt irrigating solution.

Claim 20 (new): The method of claim 17, wherein the composition is a balanced salt irrigating solution.

Claim 21 (new): The method of claim 15, wherein the composition is administered through retrobulbar or periocular injection.

Claim 22 (new): A method for treatment of a disorder of the outer retina selected from the group consisting of acute retinopathies associated with trauma, post-surgical complications,

damage associated with ocular laser therapy including photodynamic therapy (PDT), surgical light induced iatrogenic retinopathy, age related macular degeneration and retinal ischemia, said method comprising administering to a mammal a composition comprising an effective amount of one or more neurotrophic factor stimulator(s) and a pharmaceutically acceptable vehicle.

Claim 23 (new): The method of claim 22, wherein the neurotrophic factor stimulator is selected from the group consisting of: AIT-082 (neotrofin), idebenone, ONO-2506, CB-1093, NS521 ((1-(1-butyl)-4-(2-oxo-1-benzimidazolone) piperidine, SS-701, KT-711 and clenbuterol.

Claim 24 (new): The method of claim 23, wherein the neurotrophic factor stimulator is AIT-082 (neotrofin).

Claim 25 (new): The method of claim 22, wherein the composition is an oral formulation.

Claim 26 (new): The method of claim 22, wherein the composition is a topical ophthalmic, or intraocular formulation.